[Efficiency of taliton in treatment of ischemic cardiomyopathy].
The aim of investigation was to assess efficiency and safety of the lypophilic beta-adrenobloker taliton (carvedilol) in patients with ischemic cardiomiopathy. 20 patients with ischemic cardiomiopathy entered an open trial, mean age 59 years. All patients received basic therapy (ACE-inhibitors, diuretics, aspirin) and taliton. Starting dose of taliton was 3,125 mg twice daily. Dose increased with 2-weekly interval till target dose 25 mg twice daily. Duration of investigation was 6 months. The efficacy of treatment was assessed by the clinical examination, the results of echocardiography and 24 h monitoring of ECG. After treatment with taliton for 6 months increased ejection fraction, left ventricle sizes and volumes decreased, on 24 monitoring of ECG ST depression decreased. There was no side effects of taliton.
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002227:Carbazoles / Q000494:pharmacology / Q000627:therapeutic use*; D009202:Cardiomyopathies / Q000150:complications* / Q000188:drug therapy*; D000077261:Carvedilol; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications* / Q000188:drug therapy*; D011412:Propanolamines / Q000494:pharmacology / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol